NSETrading Window29 Sept 2026 · 29 Sept 2026, 05:53 pm

Trading Window

Emcure Pharmaceuticals Limited · EMCURE

✦ AI SummaryRegulatory

Emcure Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of unaudited financial results for the quarter and half year ending on September 30, 2026.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk8/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Emcure Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Attachments (1)

📄

EMCURE_29092026175257_IntimationofClosureofTradingWindowQ2FY27.pdf

pdf

Download →
View document text
Emcure Ref: EPL/CS/SE/0086/2026 Date: September 29, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, P J Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400 051 Mumbai- 400 001 Script Symbol: EMCURE Scrip Code/Symbol: 544210/ EMCURE Dear Sir/Madam, Subject: Intimation of Closure of Trading Window This is to inform you that pursuant to the Code of Conduct for regulating, monitoring and reporting of insider trading in the securities of the Company, framed pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended, the Trading window for trading/dealing in securities of the Company by the Designated Persons and their immediate relatives will be closed with effect from Thursday, October 01, 2026, and shall remain closed up to 48 hours after the declaration of the unaudited financial results of the Company for the quarter and half year ending on September 30, 2026. The date of the Board Meeting for consideration and approval of the unaudited financial results of the Company for the quarter and half year ending on September 30, 2026, shall be intimated in due course. The intimation is also being uploaded on the website of the Company at www.emcure.com. You are requested to take the above information on your records. Thanking you, For Emcure Pharmaceuticals Limited Amruta Yangalwar Company Secretary & Compliance Officer ICSI Membership Number: A25687 Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251